IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+20.34%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$693M
AUM Growth
+$693M
(-1.7%)
Cap. Flow
-$91.4M
Cap. Flow
% of AUM
-13.2%
Top 10 Holdings %
Top 10 Hldgs %
31.56%
Holding
95
New
31
Increased
14
Reduced
20
Closed
26
Top Buys
| 1 |
AbbVie
ABBV
|
$26.3M |
| 2 |
WBA
Walgreens Boots Alliance
WBA
|
$22.2M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
$22M |
| 4 |
Sanofi
SNY
|
$19.9M |
| 5 |
Teleflex
TFX
|
$17.5M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$50.1M |
| 2 |
argenx
ARGX
|
$34.4M |
| 3 |
McKesson
MCK
|
$21.7M |
| 4 |
Amgen
AMGN
|
$17.5M |
| 5 |
Cigna
CI
|
$17.2M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Regenxbio
RGNX
$498M
| $5.83M | 0.79% |
+325,000
| New | +$5.83M |
|
52
Revolution Medicines
RVMD
$7.43B
| $5.74M | 0.78% |
200,000
-325,000
| -62% | -$9.32M |
|
|
LBPH
53
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $5.43M | 0.74% |
900,000
+140,000
| +18% | +$844K |
|
54
Avantor
AVTR
$8.74B
| $4.57M | 0.62% |
200,000
-325,000
| -62% | -$7.42M |
|
|
SAGE
55
DELISTED
Sage Therapeutics
SAGE
| $4.33M | 0.59% |
+200,000
| New | +$4.33M |
|
56
MacroGenics
MGNX
$121M
| $4.33M | 0.59% |
+450,000
| New | +$4.33M |
|
57
Agilon Health
AGL
$497M
| $4.08M | 0.56% |
+325,000
| New | +$4.08M |
|
58
Acadia Pharmaceuticals
ACAD
$4.34B
| $4.07M | 0.55% |
+130,000
| New | +$4.07M |
|
|
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
| $3.96M | 0.54% |
450,000
+350,000
| +350% | +$3.08M |
|
60
Zentalis Pharmaceuticals
ZNTL
$123M
| $3.79M | 0.52% |
250,000
-200,000
| -44% | -$3.03M |
|
61
Fate Therapeutics
FATE
$115M
| $3.37M | 0.46% |
+900,000
| New | +$3.37M |
|
|
PDCO
62
DELISTED
Patterson Companies, Inc.
PDCO
| $2.85M | 0.39% |
+100,000
| New | +$2.85M |
|
63
Organon & Co
OGN
$2.56B
| $2.16M | 0.29% |
+150,000
| New | +$2.16M |
|
64
Teladoc Health
TDOC
$1.37B
| $2.16M | 0.29% |
100,000
-500,000
| -83% | -$10.8M |
|
65
Tarsus Pharmaceuticals
TARS
$2.44B
| $2.03M | 0.28% |
+100,000
| New | +$2.03M |
|
66
Scholar Rock
SRRK
$3.3B
| $1.88M | 0.26% |
+100,000
| New | +$1.88M |
|
67
Ventyx Biosciences
VTYX
$184M
| $1.24M | 0.17% |
500,000
+70,000
| +16% | +$173K |
|
68
Supernus Pharmaceuticals
SUPN
$2.52B
| – | – |
-220,000
| Closed | -$6.07M |
|
69
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
0
| – | – |
|
70
Revvity
RVTY
$9.68B
| – | – |
-100,000
| Closed | -$11.1M |
|
71
Roivant Sciences
ROIV
$8.6B
| – | – |
-450,000
| Closed | -$5.26M |
|
72
Replimune Group
REPL
$460M
| – | – |
-250,000
| Closed | -$4.28M |
|
73
Pfizer
PFE
$141B
| – | – |
-150,000
| Closed | -$4.98M |
|
74
Pacific Biosciences
PACB
$378M
| – | – |
-800,000
| Closed | -$6.68M |
|
75
Merck
MRK
$210B
| – | – |
-50,000
| Closed | -$5.15M |
|